Cambridge, United Kingdom

Elena Cressina

USPTO Granted Patents = 10 

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 25(Granted Patents)


Location History:

  • Nr Saffron Walden, GB (2019)
  • Nr. Saffron Walden, GB (2020)
  • Cambridge, GB (2021 - 2024)

Company Filing History:


Years Active: 2019-2025

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Innovations of Inventor Elena Cressina

Introduction

Elena Cressina is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the area of nucleotide sequencing. With a total of 10 patents to her name, Cressina's work has advanced the methodologies used in genetic research and sequencing technologies.

Latest Patents

Cressina's latest patents include innovative methods of sequencing using nucleotides with a 3' acetal blocking group. These embodiments relate to nucleotides that feature acetal 3'-OH blocking groups, providing new methods for utilizing fully functionalized nucleotides in sequencing applications. Another notable patent involves nucleotides with a 3' AOM blocking group, which details the preparation of such nucleotide molecules and their applications in sequencing.

Career Highlights

Elena Cressina is currently employed at Illumina Cambridge Limited, a leading company in the field of genomics. Her work at Illumina has positioned her as a key player in the development of advanced sequencing technologies. Cressina's innovative approaches have garnered attention and respect within the scientific community.

Collaborations

Cressina has collaborated with notable colleagues, including Xiaohai Liu and Antoine Francais. These partnerships have further enhanced her research and contributed to the success of her projects.

Conclusion

Elena Cressina's contributions to nucleotide sequencing and her innovative patents have made a significant impact in the field of biotechnology. Her work continues to influence advancements in genetic research and sequencing technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…